Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$17.05 USD
-1.05 (-5.80%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $17.18 +0.13 (0.76%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth B Momentum A VGM
Fundamental Charts
About Return on Equity (TTM)
Sarepta Therapeutics, Inc.'s return on equity, or ROE, is -1.03% compared to the ROE of the Medical - Biomedical and Genetics industry of -66.95%. While this shows that SRPT has struggled to make solid use of its equity, this metric will vary significantly from industry to industry.
Return on Equity (or ROE) is calculated as income divided by average shareholder equity (past 12 months, including reinvested earnings). The income number is listed on a company's Income Statement. Shareholder Equity (which is the difference between Total Assets and Total Liabilities) can be found on the Balance Sheet.
SRPT 17.05 -1.05(-5.80%)
Will SRPT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SRPT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SRPT
Sarepta Sells Arrowhead Stake to Fund Milestone Payment
Sarepta Soars on Q2 Earnings & Sales Beat, Resumes Elevidys Deliveries
SRPT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Sarepta Therapeutics (SRPT) Reports Q2 Earnings: What Key Metrics Have to Say
Sarepta Therapeutics (SRPT) Tops Q2 Earnings and Revenue Estimates
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
Other News for SRPT
Crossed Above 50 Day Moving Average appears for SRPT after 3.61% move
BMO Capital Remains a Hold on Sarepta Therapeutics (SRPT)
Is SRPT setting up for a drop? 50 Day Moving Average Resistance shows up after climbing 0.46%
Expert Outlook: Sarepta Therapeutics Through The Eyes Of 43 Analysts
Wall Street Analysts Are Bullish on Top Healthcare Picks